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The synthesis of a family of N-mustard analogs of S-adenosyl-L-methionine (SAM) containing azides and
alkynes at the N6-position of the adenosine base has been accomplished from commercially available
inosine. Further biochemical analysis of these analogs indicates successful modiﬁcation of pUC19 plas-
mid DNA in an enzyme-dependent fashion with DNA methyltransferases M.TaqI and M.HhaI.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Fig. 1. C8-Substituted N-mustard analogs of SAM.1. Introduction
Methylation of proteins, nucleic acids, polysaccharides, small
molecules, and lipids plays a dynamic role in cellular processes.1,2
More importantly, DNA and protein methylation have been
shown to play a critical role in the epigenetic control of gene ac-
tivity.3 To advance our understanding of how methylation events
contribute to and alter cellular function, small molecules, which
mimic the native methyl donor, S-adenosyl-L-methionine (SAM),
will hold tremendous promise by which to dissect and understand
biological methylation. Our interests in developing these tools are
reﬂected in the synthesis and biochemical study of SAM-based
analogs containing reactive functionalities capable of undergoing
chemoselective ligations.4,5
The design of SAM analogs containing these functionalities has
evolved from work carried out by Weinhold et al. to generate
simple analogs containing aziridines6e8 to work by S. Rajski to in-
corporate azides capable of undergoing copper-catalyzed azide-
alkyne cycloaddition (CuAAC or Click) chemistry or the Staudinger
ligation.9,10 Pivotal to the advancement of such analogs as useful
biochemical tools was the incorporation of the amino acid recog-
nition moiety found in SAM (1, Fig. 1). Incorporating the amino acid
has proven to be a more effective SAM mimic compared to the
aziridine-functionalized SAM analogs, as demonstrated by its efﬁ-
cient enzymatic incorporation onto DNA, small molecule, andmail address: comstolr@wfu.
Ltd. This is an open access article upeptide substrates.11e13 More recently, work carried out in our
laboratory has brought together the requisite amino acidmoiety for
improved enzyme-cofactor interactions, along with the reactive
azides and alkynes at the C8-position, to generate N-mustard SAM
analogs 2e4 (Fig. 1).14,15 The utility of 2e4 has been demonstrated
with a small panel of DNA methyltransferases (MTases) to undergonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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DNA products.
While the C8-substituted analogs 2e4 have proven useful with
a small panel of DNA methyltransferases, the accessibility of this
position may be limited in a number of other methyltransferases,
including protein methyltransferases.16,17 Analysis of known crystal
structures indicates the 6-position of the adenosine base to be ac-
cessible and supports expansion of our small library of SAM analogs
(Fig. 2) to contain alkyne (5aec) and azide (6aeb) handles at theN6
position of the adenine base. We anticipate that this family of SAM
analogs may be accommodated by classes of MTases that do not
tolerate C8-substitution andwill be important biochemical tools for
future studies in identifying both sites and substrates of biological
methylation.Fig. 2. N6-Substituted azide- and alkyne N-mustard analogs of SAM.2. Results and discussion
In the early stages of developing a synthetic pathway to obtain
5aec and 6aeb, we sought to simplify and shorten the synthetic
pathway to generate N-mustard analogs of SAM from previously
reported methods.14,15 Although incorporation of the amino acid
functionality would again be incorporated via reductive amination
using previously described procedures, it was anticipated that
production of the requisite ethanolamine intermediate on the ri-
bose sugar could be easily improved upon. Ultimately, a procedure
to aminate the 6-position of the adenine base to incorporate the
desired alkyne and azide linkers was pivotal to the completion of
analogs 5a-c and 6aeb.
Investigation of previously reported transformations that gen-
erate similar alkyl linkages at the 6-position of the adenine base
indicated two potential starting points. The ﬁrst strategy either
began with or carried out a multi-step synthesis to generate 6-
chloropurine riboside derivatives, followed by displacement of
the chloride with primary amines, to yield the desired amination
product.18,19 Alternatively, direct incorporation of primary amines
to the 6-position through a one-step coupling with inosine using
BOP derivatives has been shown to occur in high yields.20,21 Ulti-
mately, we chose to proceed with a PyBOP coupling to inosine, as
a signiﬁcant reduction in the number of transformations to in-
corporate the alkyne and azide functionalities was required. While
it was envisioned that this coupling to the inosine base could occur
at multiple stages in the synthetic pathway, it was carried out early
on to generate intermediates that were more non-polar and easier
to manipulate synthetically.
Beginning with isopropylidene inosine,22 a small panel of al-
kyne- and azide-functionalized amines were coupled to the 6-
position with PyBOP in the presence of DIPEA to generate N6-
substituted adenosines 8aee in high yields (Scheme 1). In-
corporation of the desired ethanolamine functionality was carried
out in a two-step process via activation of the 50 ribose alcohol with
methanesulfonyl chloride to obtain mesylates 9aee, which were
immediately displaced with ethanolamine to afford alcohols 10aee
in moderate yields.23 Subsequent incorporation of the amino acidfunctionality followed previously reported procedures via re-
ductive amination with tert-Butyl (S)-2-[N-(tert-butoxycarbonyl)
amino]-4-oxobutanoate24 in the presence of NaBH3CN and acetic
acid to provide the fully protected amino alcohols 11aee. To com-
plete the synthesis, incorporation of the requisite iodine was di-
rectly followed by global deprotection with 4 N HCl in dioxane,14,15
to provide the desired alkyne- and azide -substituted N-mustard
SAM analogs, 5aec and 6aeb. It is important to note that iodination
of the alcohol requires the reagents to be added in the proper order
to prevent reduction of azides 11d and 11e to a primary amine by
the triphenylphosphine.
Having synthesized the small panel of N6-functionalized N-
mustard analogs of SAM, we next set out to investigate their ability
to be enzymatically transferred to DNA in a site-speciﬁc manner.
These experiments employed pUC19 plasmid DNA as the substrate,
as it is considered a good model for a DNA MTase due to its large
size and its closer resemblance to genomic DNA. The generality of
the SAM analogs amongst various DNA MTases was assessed using
a small panel of prokaryotic enzymes, including M.TaqI25 and
M.HhaI,26 which methylate adenine N6 and cytosine C5,
respectively.
Enzymatic transfer of 5aec and 6aeb to R.EcoRI-linearized
plasmid DNA was carried out using the well-established re-
striction/protection assay,10 which exploits the resistance of DNA
modiﬁed at the site corresponding to the MTase of interest to
strand cleavage by its’ restriction endonuclease. Experiments
employing M.TaqI are shown in Fig. 3A and B and indicate suc-
cessful transfer of 5aec and 6aeb to pUC19. Examination of Fig. 3A
for the alkyne analogs 5aec demonstrate an increase in the amount
of DNA alkylation with a gradient ranging from 0.1 to 10 mM (lanes
3e5, 7e9 and 11e13) for the three analogs, relative to the DNA
controls in lanes 1 and 14, as reﬂected by the increased protection
from R.TaqI digestion. At the highest concentration of analog in
lanes 5, 9, and 13, a signiﬁcant portion of the plasmid DNA is full
length and smaller restriction fragments almost completely dis-
appear, indicating nearly quantitative transfer. In the absence of
M.TaqI, protection of the DNA was not observed (lanes 2, 6 and 10)
and indicates that non-speciﬁc DNA alkylation by any of the analogs
is not sufﬁcient to protect TaqI-mediated plasmid scission. Similar
trends were observed for the azide analogs, as shown in Fig. 3B.
Nearly quantitative transfer was observed, as an increase in DNA
alkylation (lanes 3e5 and 7e9) with a gradient of 6a and 6b, rel-
ative to the controls in lanes 1 and 10. Again, no protection of the
DNA was detected (lanes 2 and 6) in the absence of M.TaqI. The
results demonstrated here agrees with the previous report of
M.TaqI successfully transferring a Cy3 functionalized aziridine SAM
analog linked to the 6-position of the adenine base with plasmid
DNA.27
Having demonstrated successful transfer of the SAM analogs to
plasmid DNAwith M.TaqI, the generality of 5aec and 6aeb to serve
as cofactors for another DNA MTase was explored. Speciﬁcally,
M.HhaI-mediated transfer of 5aec and 6aeb to pUC19 was carried
out. Reaction analysis using the restriction/protection assay dem-
onstrated successful incorporation of 5aec and 6aeb to plasmid
DNA (see Fig. S1) and supports the ability of M.HhaI to accommo-
date substitution at theN6 position. These results reveal for the ﬁrst
time the ability of M.HhaI to bind and catalyze the transfer of SAM
analogs substituted at the 6-position, indicating its ﬂexibility in
accommodating substitution at multiple positions on the adenine
base.
3. Conclusions
In conclusion, we have successfully synthesized a small library
of N6 functionalized alkyne and azide N-mustard analogs (5aec
and 6aeb) of SAM to expand our chemical toolbox to study
Scheme 1. Synthesis of N6-substituted SAM analogs 5aec and 6aeb.
Fig. 3. DNA alkylation reactions with M.TaqI. Restriction/protection assay was carried
out with R.EcoRI-linearized pUC19 for analogs 5aec and 6aeb. The extent of DNA
modiﬁcation was analyzed on a 2% agarose gel containing ethidium bromide. A. Lane
components: 1) DNA, R.TaqI; 2) DNA, 5a (10 mM), R.TaqI; 3) DNA, 5a (100 nM), M.TaqI,
R.TaqI; 4) DNA, 5a (1 mM), M.TaqI, R.TaqI; 5) DNA, 5a (10 mM), M.TaqI, R.TaqI; 6e9)
same as 2e5, but with 5b; 10e13) same as 2e5, but with 5c; 14) DNA. B. Lane com-
ponents: 1) DNA, R.TaqI; 2) DNA, 6a (10 mM), R.TaqI; 3) DNA, 6a (100 nM), M.TaqI,
R.TaqI; 4) DNA, 6a (1 mM), M.TaqI, R.TaqI; 5) DNA, 6a (10 mM), M.TaqI, R.TaqI; 6e9)
same as 2e5, but with 6b; 10) DNA.
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thetic route taken here signiﬁcantly improved on those previously
reported for 2e4, as the number of required transformations is
reduced to 7 steps beginning from inosine (compared to 12 and 11
steps for 3 and 4, respectively). Due to the efﬁciency and simplicity
of the synthetic transformations described here, it is feasible that
such steps may be used in future efforts to not only shorten and
improve the syntheses of 2e4, but to also generate additional SAM
analogs bearing reactive functionalities.
The biological utility of 5aec and 6aeb was further demon-
strated by their near quantitative MTase-dependentmodiﬁcation of
plasmid DNA. Plasmid DNA experiments indicated that both M.TaqI
and M.HhaI were able to tolerate substitution at the N6 position of
the adenine base. Based on these ﬁndings, future experiments to
investigate additional MTases, including the mammalian DNA
MTase DNMT1 and protein MTase PRMT1, to accommodate and
catalyze the transfer of functionalized N-mustard analogs must be
carried out. Such experiments will be essential to validate the SAM
analogs described here as biochemical probes of DNA and protein
methylation for future cell-based studies.4. Experimental
4.1. General methods
All reagents and solvents were purchased from commercial
sources and used without additional puriﬁcation. Anhydrous sol-
vents were obtained from a Meyer solvent system. Reactions were
performed at room temperature under argon, unless otherwise
indicated. 1H NMR spectrawere recorded at either 300 or 500MHz;
13C NMR spectra were recorded at either 75 or 125 MHz, with the
solvent peak used as the internal standard. 2D NMR spectra were
recorded at 500 MHz. Chemical shifts are reported in d (parts per
M. Ramadan et al. / Tetrahedron 70 (2014) 5291e52975294million). Analytical and semi-preparative HPLC procedures are
described in Supplementary data.
For the purposes of biological experiments, solutions of 5aec
and 6aeb were made up using H2SO4 (2.5 mM), and the concen-
trations of these samples were determined by UV/Vis spectroscopy.
By using the absorption values obtained at 260 nm and a molar
extinction constant of 9710 M1 cm1 (for 5a), 10,970 M1 cm1
(for 5b), 11,270 M1 cm1 (for 5c), 12,370 M1 cm1 (for 6a), and
11,530 M1 cm1 (for 6b), stock solution concentrations were cal-
culated using Beer’s law. Stock solutions were stored at 80 C and
used within 2 weeks.
pUC19, all enzymes, and their corresponding buffers were ob-
tained from New England Biolabs. All agarose gels were prepared
with a high-melt agarose in 1X TAE. Ethidium bromide imageswere
obtained with a ChemiDoc MP system (Bio-Rad).
4.2. General procedure for PyBOP coupling
N,N-Diisopropylethylamine (1.04 mL, 6.0 mmol) was added to
a solution of 20,30-O-Isopropylidene inosine (7)22 (0.925 g,
3.0 mmol) and PyBOP (2.341 g, 4.5 mmol) in 6.0 mL HPLC grade
acetonitrile and stirred until the solution turned clear (15 min). The
required alkyne or azide amine (6.0 mmol) was added drop wise
and the reaction was stirred overnight. The reaction was diluted
with Et2O and washed twice each with 1 M acetic acid, saturated
NaHCO3, and brine. The organic layer was dried over Na2SO4 and
concentrated. The crude residue was puriﬁed by column chroma-
tography (silica gel, 4:1 to 1:2 HexaneeEtOAc).
4.2.1. N6-(Prop-200-ynyl)-20,30-bis-(O-isopropylidene) adenosine
(8a). The reaction was carried out with propargylamine to obtain
8a (0.90 g, 87%) as a white foam. Mp 134e137 C. 1H NMR (CD3OD)
d 8.30 (s, 2H), 6.17 (d, J¼3.5 Hz, 1H), 5.29 (dd, J¼6.1, 3.5 Hz, 1H), 5.05
(dd, J¼6.1, 2.4 Hz, 1H), 4.43e4.37 (m, 3H), 3.81 (dd, J¼12.1, 3.5 Hz,
1H), 3.73 (dd, J¼12.1, 3.9 Hz, 1H), 2.62 (t, J¼2.5 Hz, 1H), 1.63 (s, 3H),
1.39 (s, 3H); 13C NMR (CD3OD) d 155.6, 153.7, 149.6, 141.6, 121.3,
115.3, 92.9, 88.1, 85.3, 83.0, 81.1, 72.2, 63.6, 30.9, 27.6, 25.5. HRMS-
ESI: calcd for C16H19N5O4 (MþNaþ) 368.1329, obsd 368.1330.
4.2.2. N6-(But-300-ynyl)-20,30-bis-(O-isopropylidene) adenosine
(8b). The reaction was carried out with 3-butyn-1-amine to obtain
8b (0.90 g, 84%) as a white foam. Mp 50e52 C. 1H NMR (CD3OD)
d 8.27 (s, 1H), 8.25 (s, 1H), 6.14 (d, J¼3.6, 1H), 5.27 (dd, J¼6.1, 3.6 Hz,
1H), 5.04 (dd, J¼6.1, 2.3 Hz, 1H), 4.40e4.36 (m, 1H), 3.82e3.68 (m,
4H), 2.57 (td, J¼7.0, 2.7 Hz, 2H), 2.32 (t, J¼2.6 Hz, 1H), 1.62 (s, 3H),
1.38 (s, 3H); 13C NMR (CD3OD) d 156.0, 153.7, 149.3, 141.3, 121.1,
115.2, 92.9, 88.0, 85.2, 82.9, 82.3, 71.0, 63.6, 40.7, 27.6, 25.5, 20.0.
HRMS-ESI: calcd for C17H21N5O4 (MþNaþ) 382.1486, obsd 382.1487.
4.2.3. N6-(Hex-500-ynyl)-20,30-bis-(O-isopropylidene) adenosine
(8c). The reaction was carried out with 5-hexyn-1-amine to obtain
8c (1.05 g, 90%) as a white foam. Mp 78e80 C. 1H NMR (CD3OD)
d 8.26 (s, 1H), 8.22 (s, 1H), 6.14 (d, J¼3.6 Hz, 1H), 5.27 (dd, J¼6.1,
3.6 Hz, 1H), 5.04 (dd, J¼6.1, 2.3 Hz, 1H), 4.39e4.36 (m,1H), 3.80 (dd,
J¼12.2, 3.4 Hz, 1H), 3.71 (dd, J¼12.2, 3.9 Hz, 1H), 3.62 (br s, 2H),
2.27e2.19 (m, 3H), 1.83e1.76 (m, 2H), 1.68e1.63 (m, 2H), 1.61 (s,
3H), 1.38 (s, 3H); 13C NMR (CD3OD) d 156.3, 153.8, 149.1, 141.1, 121.0,
115.2, 92.9, 88.0, 85.2, 84.7, 83.0, 69.8, 63.6, 41.1, 29.7, 27.6, 27.0,
25.6,18.8. HRMS-ESI: calcd for C19H25N5O4 (MþNaþ) 410.1799, obsd
410.1800.
4.2.4. N6-(300-Azidopropyl)-20,30-bis-(O-isopropylidene) adenosine
(8d). The reaction was carried out with 3-azidopropan-1-amine16
to obtain 8d (1.02 g, 87%) as a light yellow oil. 1H NMR (CD3OD)
d 8.26 (s, 1H), 8.24 (s, 1H), 6.13 (d, J¼3.6 Hz, 1H), 5.26 (dd, J¼6.1,
3.6 Hz, 1H), 5.03 (dd, J¼6.1, 2.3 Hz, 1H), 4.39e4.35 (m, 1H), 3.80 (dd,J¼12.2, 3.4 Hz,1H), 3.74e3.68 (m, 3H), 3.44 (t, J¼6.7 Hz, 2H),1.94 (p,
J¼6.7 Hz, 2H), 1.61 (s, 3H), 1.37 (s, 3H); 13C NMR (CD3OD) d 156.4,
153.8, 141.2, 121.1, 115.3, 92.9, 88.0, 85.3, 83.0, 63.6, 50.1, 29.9, 27.6,
25.6; additional carbons identiﬁed by HMBC, (CDCl3) d 147.2, 37.9.
HRMS-ESI: calcd for C16H22N8O4 (MþNaþ) 413.1656, obsd 413.1657.
4.2.5. N6-(400-Azidobutyl)-20,30-bis-(O-isopropylidene) adenosine
(8e). The reaction was carried out with 4-azidobutan-1-amine16 to
obtain 8e (1.10 g, 91%) as a yellow oil. 1H NMR (CDCl3) d 8.32 (s, 1H),
7.79 (s, 1H), 6.77 (br s, 1H), 6.15 (bt, J¼5.5 Hz, 1H), 5.85 (d, J¼4.9 Hz,
1H), 5.23e5.19 (m, 1H), 5.12 (dd, J¼6.0, 1.2 Hz, 1H), 4.55e4.53 (m,
1H), 3.98 (dd, J¼12.8, 1.6 Hz, 1H), 3.81e3.76 (m, 1H), 3.69 (br s, 2H),
3.34 (t, J¼6.3 Hz, 2H),1.80e1.68 (m, 4H),1.64 (s, 3H),1.38 (s, 3H); 13C
NMR (CDCl3) d 155.4, 152.8, 147.5, 139.6, 121.3, 114.1, 94.5, 86.2, 83.1,
81.8, 63.5, 51.2, 40.1, 27.8, 27.1, 26.4, 25.4. HRMS-ESI: calcd for
C17H24N8O4 (MþNaþ) 427.1813, obsd 427.1814.
4.3. General procedure for mesylation
To a solution of the N6 substituted adenosine (1.5 mmol) in
7.5 mL CH2Cl2 was added triethylamine (0.50 mL, 3.6 mmol) and
methanesulfonyl chloride (140 mL, 1.8 mmol). The reaction was
stirred for 1 h and then quenched with saturated NH4Cl. The layers
were separated and the organic layer was washed twice with brine.
The combined aqueous layers were extracted twice with CH2Cl2,
dried over Na2SO4 and concentrated. Due to the inherent reactivity
of the mesylate, melting point and HRMSwas not performed (LRMS
is provided). The crude residue was puriﬁed by column chroma-
tography (silica gel, 50:1 CH2Cl2:MeOH).
4.3.1. N6-(Prop-200-ynyl)-50-methanesulfonate-20,30-bis-(O-iso-
propylidene) adenosine (9a). The reaction was carried out with 8a
to give mesylate 9a (0.552 g, 87%) as a white foam. 1H NMR (CDCl3)
d 8.42 (s, 1H), 7.89 (s, 1H), 6.31 (t, J¼5.6 Hz, 1H), 6.12 (d, J¼2.0 Hz,
1H), 5.47 (dd, J¼6.4, 2.1 Hz, 1H), 5.16 (dd, J¼6.3, 3.0 Hz, 1H),
4.54e4.38 (m, 5H), 2.89 (s, 3H), 2.27 (t, J¼2.6 Hz, 1H), 1.61 (s, 3H),
1.39 (s, 3H); 13C NMR (CDCl3) d 154.3, 153.3, 148.7, 139.9, 120.7,
114.9, 91.0, 84.9, 84.1, 81.5, 80.2, 71.7, 68.6, 37.6, 30.5, 27.2, 25.4.
LRMS-ESI: calcd for C17H21N5O6S (MþHþ) 424.1, obsd 424.2.
4.3.2. N6-(But-300-ynyl)-50-methanesulfonate-20,3 0-bis-(O-iso-
propylidene) adenosine (9b). The reaction was carried out with 8b
to give mesylate 9b (0.551 g, 84%) as a white foam. 1H NMR (CDCl3)
d 8.37 (s, 1H), 7.86 (s, 1H), 6.20e6.16 (m, 1H), 6.11 (d, J¼2.1 Hz, 1H),
5.48 (dd, J¼6.3, 2.1 Hz, 1H), 5.17 (dd, J¼6.4, 3.0 Hz, 1H), 4.53e4.41
(m, 3H), 3.85 (br s, 2H), 2.91 (s, 3H), 2.60 (td, J¼6.5, 2.6 Hz, 2H), 2.04
(t, J¼2.6 Hz, 1H), 1.62 (s, 3H), 1.40 (s, 3H); 13C NMR (CDCl3) d 154.8,
153.3, 148.3, 139.5, 120.6, 114.7, 90.9, 84.8, 84.1, 81.6, 81.5, 70.4, 68.6,
39.3, 37.5, 27.1, 25.3, 19.6. LRMS-ESI: calcd for C18H23N5O6S (MþHþ)
438.1, obsd 438.2.
4.3.3. N6-(Hex-500-ynyl)-5 0-methanesulfonate-20,30-bis-(O-iso-
propylidene) adenosine (9c). The reactionwas carried out with 8c to
give mesylate 9c (0.621 g, 89%) as a light yellow foam. 1H NMR
(CDCl3) d 8.36 (s, 1H), 7.83 (s, 1H), 6.11 (d, J¼2.0 Hz, 1H), 5.82 (bt,
J¼6.0 Hz, 1H), 5.48 (dd, J¼6.3, 2.0 Hz, 1H), 5.18e5.15 (m, 1H),
4.55e4.39 (m, 3H), 3.69 (br s, 2H), 2.90 (s, 3H), 2.27 (td, J¼7.0,
2.7 Hz, 2H), 1.97 (t, J¼2.7 Hz, 1H), 1.87e1.78 (m, 2H), 1.71e1.63 (m,
2H), 1.62 (s, 3H), 1.40 (s, 3H); 13C NMR (CDCl3) d 154.9, 153.1, 147.9,
139.1, 120.1, 114.5, 90.6, 84.6, 84.0, 83.9, 81.2, 68.7, 68.6, 39.9, 37.2,
28.6, 26.9, 25.5, 25.1, 17.9. LRMS-ESI: calcd for C20H27N5O6S (MþHþ)
466.2, obsd 466.2.
4.3.4. N6-(300-Azidopropyl)-50-methanesulfonate-20,30-bis-(O-iso-
propylidene) adenosine (9d). The reaction was carried out with 8d
to give mesylate 9d (0.667 g, 95%) as a light yellow foam. 1H NMR
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J¼6.3, 2.1 Hz, 1H), 5.17 (dd, J¼6.2, 2.9 Hz, 1H), 4.55e4.40 (m, 3H),
3.78 (br s, 2H), 3.45 (t, J¼6.6 Hz, 2H), 2.91 (s, 3H), 1.98 (p, J¼6.6 Hz,
2H), 1.62 (s, 3H), 1.40 (s, 3H); 13C NMR (CDCl3) d 155.1, 153.4, 148.3,
139.4, 120.5, 114.8, 91.0, 84.9, 84.1, 81.5, 68.7, 49.2, 38.1, 37.6, 29.1,
27.2, 25.4. LRMS-ESI: calcd for C17H24N8O6S (MþHþ) 469.2, obsd
469.2.
4.3.5. N6-(400-Azidobutyl)-50-methanesulfonate-20,30-bis-(O-iso-
propylidene) adenosine (9e). The reactionwas carried outwith 8e to
give mesylate 9e (0.607 g, 84%) as a light yellow foam. 1H NMR
(CDCl3) d 8.29 (s, 1H), 7.77 (s, 1H), 6.04 (d, J¼2.0 Hz, 1H), 5.80 (bt,
J¼6.0 Hz, 1H), 5.41 (dd, J¼6.4, 2.1 Hz, 1H), 5.10 (dd, J¼6.5, 2.9 Hz,
1H), 4.48e4.32 (m, 3H), 3.64 (br s, 2H), 3.28 (t, J¼6.4 Hz, 2H), 2.84
(s, 3H), 1.77e1.59 (m, 4H), 1.55 (s, 3H), 1.33 (s, 3H); 13C NMR (CDCl3)
d 155.1, 153.4, 148.1, 139.3, 120.5, 114.8, 91.0, 84.9, 84.1, 81.5, 68.7,
51.2, 40.1, 37.6, 27.2, 27.1, 26.3, 25.4. LRMS-ESI: calcd for
C18H26N8O6S (MþHþ) 483.2, obsd 483.2.
4.4. General procedure for ethanolamine displacement
The N6 substituted mesylate (1.0 mmol) was brought up in 3 mL
of 2-aminoethanol (50 mmol) and stirred for 3 days. The volatiles
were evaporated off under high vacuum with gentle heating using
a distillation apparatus. Upon addition of brine to the resulting
material, the product was extractedwith EtOAc, washedwith brine,
dried over Na2SO4 and concentrated. The crude residue was puri-
ﬁed by column chromatography (silica gel, 9:1 to 7:3
CH2Cl2eMeOH).
4.4.1. N6-(Prop-200-ynyl)-50-N-hydroxyethyl-50-deoxy-20,30-bis-(O-
isopropylidene) adenosine (10a). The reaction was carried out with
9a to obtain 10a as a white foam (0.271 g, 70%). Mp 74e76 C. 1H
NMR (CDCl3) d 8.40 (s, 1H), 7.89 (s, 1H), 6.57 (br s, 1H), 5.99 (d,
J¼3.1 Hz, 1H), 5.47 (dd, J¼6.4, 3.0 Hz, 1H), 5.03 (dd, J¼6.4, 3.3 Hz,
1H), 4.45 (br s, 2H), 4.38e4.33 (m, 1H), 3.63 (t, J¼5.1 Hz, 2H), 2.95
(dd, J¼12.6, 4.6 Hz, 1H), 2.90 (dd, J¼12.6, 6.2 Hz, 1H), 2.83e2.68 (m,
2H), 2.50 (br s, 2H), 2.26 (t, J¼2.5 Hz, 1H), 1.61 (s, 3H), 1.38 (s, 3H);
13C NMR (CDCl3) d 154.2, 153.3, 148.9, 139.9, 120.8, 114.7, 91.1, 85.8,
83.6, 82.4, 80.2, 71.6, 61.0, 51.3, 51.1, 30.6, 27.4, 25.5. HRMS-ESI:
calcd for C18H24N6O4 (MþNaþ) 411.1751, obsd 411.1753.
4.4.2. N6-(But-300-ynyl)-50-N-hydroxyethyl-50-deoxy-20,30-bis-(O-
isopropylidene) adenosine (10b). The reaction was carried out with
9b to obtain 10b as a white gum (0.273 g, 68%). 1H NMR (CDCl3)
d 8.35 (s, 1H), 7.87 (s, 1H), 6.38 (bt, J¼6.6 Hz, 1H), 6.00 (d, J¼3.0 Hz,
1H), 5.44 (dd, J¼6.5, 3.0 Hz, 1H), 5.04 (dd, J¼6.4, 3.4 Hz, 1H),
4.42e4.37 (m, 1H), 3.81 (br s, 2H), 3.65 (t, J¼5.1 Hz, 2H), 3.47 (br s,
2H), 3.09e2.98 (m, 2H), 2.90e2.75 (m, 2H), 2.58 (td, J¼6.6, 2.7 Hz,
2H), 2.05 (t, J¼2.6 Hz, 1H), 1.61 (s, 3H), 1.38 (s, 3H); 13C NMR (CDCl3)
d 154.8, 153.3, 139.6, 120.5, 114.9, 91.0, 85.0, 83.6, 82.3, 81.7, 70.4,
60.3, 51.0, 50.7, 27.4, 25.5, 19.7; additional carbons identiﬁed by
HMBC, (CDCl3) d 148.5, 39.3. HRMS-ESI: calcd for C19H26N6O4
(MþNaþ) 425.1908, obsd 425.1911.
4.4.3. N6-(Hex-500-ynyl)-50-N-hydroxyethyl-50-deoxy-20,30-bis-(O-
isopropylidene) adenosine (10c). The reaction was carried out with
9c to obtain 10c as a white gum (0.245 g, 57%). 1H NMR (CDCl3)
d 8.35 (s, 1H), 7.82 (s, 1H), 5.98 (d, J¼3.1 Hz, 1H), 5.85 (br s, 1H), 5.49
(dd, J¼6.5, 3.1 Hz, 1H), 5.06 (dd, J¼6.5, 3.2 Hz, 1H), 4.39e4.34 (m,
1H), 3.74e3.66 (m, 2H), 3.63 (t, J¼5.2 Hz, 2H), 2.97 (dd, J¼12.7,
4.6 Hz,1H), 2.92 (dd, J¼12.6, 5.9 Hz,1H), 2.86e2.70 (m, 2H), 2.42 (br
s, 2H), 2.26 (td, J¼7.0, 2.6 Hz, 2H), 1.96 (t, J¼2.6 Hz, 1H), 1.87e1.77
(m, 2H),1.71e1.63 (m, 2H),1.61 (s, 3H),1.38 (s, 3H); 13C NMR (CDCl3)
d 155.2, 153.4, 139.4, 120.7, 114.7, 91.2, 85.6, 84.1, 83.5, 82.4, 68.9,
60.9, 51.3, 51.0, 28.9, 27.5, 25.8, 25.6, 18.3; additional carbonsidentiﬁed by HMBC, (CDCl3) d 148.2, 40.0. HRMS-ESI: calcd for
C21H30N6O4 (MþNaþ) 453.2221, obsd 453.2223.
4.4.4. N6-(300-Azidopropyl)-50-N-hydroxyethyl-50-deoxy-20,30-bis-(O-
isopropylidene) adenosine (10d). The reaction was carried out with
9d to obtain 10d as a yellow oil (0.260 g, 60%). 1H NMR (CDCl3)
d 8.36 (s, 1H), 7.85 (s, 1H), 6.13 (bt, J¼5.9 Hz, 1H), 5.99 (d, J¼3.1 Hz,
1H), 5.49 (dd, J¼6.4, 3.1 Hz, 1H), 5.05 (dd, J¼6.4, 3.2 Hz, 1H),
4.40e4.36 (m,1H), 3.79e3.72 (m, 2H), 3.64 (t, J¼5.1 Hz, 2H), 3.45 (t,
J¼6.6 Hz, 2H), 3.00e2.88 (m, 2H), 2.86e2.70 (m, 2H), 2.52 (br s, 2H),
1.97 (p, J¼6.7 Hz, 2H), 1.62 (s, 3H), 1.39 (s, 3H); 13C NMR (CDCl3)
d 155.1,153.4,139.6,120.7,114.7, 91.2, 85.6, 83.5, 82.4, 61.0, 51.3, 51.0,
49.2, 29.1, 27.4, 25.5; additional carbons identiﬁed by HMBC,
(CDCl3) d 148.3, 38.0. HRMS-ESI: calcd for C18H27N9O4 (MþNaþ)
456.2078, obsd 456.2080.
4.4.5. N6-(400-Azidobutyl)-50-N-hydroxyethyl-50-deoxy-20,30-bis-(O-
isopropylidene) adenosine (10e). The reaction was carried out with
9e to obtain 10e as a yellow oil (0.290 g, 65%). 1H NMR (CDCl3) d 8.36
(s, 1H), 7.84 (s, 1H), 5.98 (d, J¼3.2 Hz, 1H), 5.92 (br s, 1H), 5.49 (dd,
J¼6.5, 3.2 Hz, 1H), 5.06 (dd, J¼6.5, 3.3 Hz, 1H), 4.40e4.35 (m, 1H),
3.70 (br s, 2H), 3.63 (t, J¼5.2 Hz, 2H), 3.35 (t, J¼6.3 Hz, 2H),
2.99e2.90 (m, 2H), 2.88e2.70 (m, 2H), 2.36 (br s, 2H), 1.82e1.65 (m,
4H), 1.62 (s, 3H), 1.39 (s, 3H); 13C NMR (CDCl3) d 155.2, 153.4, 139.5,
120.7,114.7, 91.2, 85.7, 83.5, 82.4, 61.0, 51.3, 51.3, 51.1, 27.5, 27.2, 26.4,
25.6; additional carbons identiﬁed by HMBC, (CDCl3) d 148.3, 39.9.
HRMS-ESI: calcd for C19H29N9O4 (MþNaþ) 470.2235, obsd
470.2236.
4.5. General procedure for reductive amination
NaBH3CN (0.048 g, 0.771 mmol) and glacial acetic acid (29.4 mL,
0.514 mmol) were added to a solution of the N6-substituted N-
hydroxyethyl adenosine (0.566 mmol) and tert-butyl (S)-2-[N-(tert-
butoxycarbonyl)amino]-4-oxobutanoate24 (0.1405 g, 0.514 mmol)
in 2 mL dry MeOH. The reaction mixture was stirred overnight.
After diluting the reaction with EtOAc and saturated NaHCO3, the
organic layer was washed with saturated NaHCO3, dried over
Na2SO4 and concentrated. The crude residue was puriﬁed by col-
umn chromatography (silica gel, 8:4:2:1 Pet Ether/EtOAc/CH2Cl2/
MeOH).
4.5.1. N6-(Prop-200-ynyl)-50-(Na-Boc-diaminobutyric acid O-tert-bu-
tyl ester)-50-N-hydroxyethyl-50-deoxy-20,30-bis-(O-isopropylidene)
adenosine (11a). The reaction was carried out with 10a to yield 11a
(0.250 g, 68%) as awhite foam.Mp 64e68 C. 1H NMR (CDCl3) d 8.42
(s, 1H), 7.88 (s, 1H), 6.04 (d, J¼2.1 Hz, 1H), 6.01 (br s, 1H), 5.45 (dd,
J¼6.5, 2.0 Hz, 1H), 5.39 (d, J¼8.2 Hz 1H), 5.06 (dd, J¼6.5, 4.0 Hz, 1H),
4.51e4.45 (bm, 2H), 4.31 (td, J¼6.8, 4.0 Hz, 1H), 4.24e4.18 (bm, 1H),
3.58e3.51 (m, 1H), 3.46e3.39 (m, 1H), 2.84 (dd, J¼13.5, 6.8 Hz, 1H),
2.71e2.47 (m, 5H), 2.27 (t, J¼2.5 Hz, 1H), 1.99e1.91 (m, 1H),
1.74e1.64 (m, 2H), 1.61 (s, 3H), 1.45 (s, 18H), 1.39 (s, 3H); 13C NMR
(CDCl3) d 171.9, 155.6, 154.3, 153.2, 148.9, 140.1, 120.8, 114.8, 90.6,
85.5, 84.1, 83.5, 82.0, 80.2, 79.9, 71.6, 59.5, 57.4, 56.5, 52.8, 51.3, 30.6,
30.0, 28.5, 28.1, 27.3, 25.6. HRMS-ESI: calcd for C31H47N7O8
(MþNaþ) 668.3378, obsd 668.3376.
4.5.2. N6-(But-300-ynyl)-50-(Na-Boc-diaminobutyric acid O-tert-bu-
tyl ester)-50-N-hydroxyethyl-50-deoxy-20,30-bis-(O-isopropylidene)
adenosine (11b). The reactionwas carried out with 10b to yield 11b
(0.283 g, 76%) as awhite foam. Mp 60e62 C. 1H NMR (CDCl3) d 8.35
(s, 1H), 7.85 (s, 1H), 6.15 (br s, 1H), 6.02 (d, J¼2.1 Hz, 1H), 5.44e5.41
(m 2H), 5.05 (dd, J¼6.5, 4.0 Hz, 1H), 4.29 (td, J¼6.8, 4.0 Hz, 1H),
4.24e4.20 (br m, 1H), 3.82 (br s, 2H), 3.55e3.52 (m, 1H), 3.44e3.41
(m, 1H), 2.85 (dd, J¼13.4, 6.8 Hz, 1H), 2.69e2.49 (m, 8H), 2.03 (t,
J¼2.6 Hz, 1H), 1.99e1.94 (m,1H), 1.71e1.66 (m,1H), 1.60 (s, 3H), 1.44
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154.9, 153.3, 139.8, 114.8, 90.5, 85.5, 84.1, 83.5, 82.1, 81.6, 79.9, 70.4,
59.4, 57.4, 56.3, 52.7, 51.0, 30.0, 28.5, 28.1, 27.3, 25.6, 19.8; additional
carbons identiﬁed by HMBC, (CDCl3) d 148.2, 120.5, 39.2. HRMS-ESI:
calcd for C32H49N7O8 (MþNaþ) 682.3535, obsd 682.3535.
4.5.3. N6-(Hex-500-ynyl)-50-(Na-Boc diaminobutyric acid O-tert-butyl
ester)-50-N-hydroxyethyl-50-deoxy-20,30-bis-(O-isopropylidene) aden-
osine (11c). The reaction was carried out with 10c to yield 11c
(0.263 g, 68%) as awhite foam. 1HNMR (CDCl3) d 8.34 (s,1H), 7.82 (s,
1H), 6.02 (d, J¼2.0 Hz, 1H), 5.84 (br s, 1H), 5.44e5.41 (m, 2H), 5.05
(dd, J¼6.5, 4.0 Hz, 1H), 4.29 (td, J¼6.8, 4.0 Hz, 1H), 4.24e4.20 (br m,
1H), 3.67 (br s, 2H), 3.56e3.52 (m, 1H), 3.43e3.40 (m, 1H),
2.87e2.83 (m, 1H), 2.69e2.49 (m, 5H), 2.25 (td, J¼7.0, 2.7 Hz, 2H),
2.00e1.94 (m, 2H), 1.84e1.78 (m, 2H), 1.71e1.62 (m, 3H), 1.60 (s,
3H), 1.44 (s, 9H), 1.43 (s, 9H), 1.39 (s, 3H); 13C NMR (CDCl3) d 172.0,
155.7, 155.1, 153.4, 139.5, 120.6, 114.7, 90.5, 85.4, 83.5, 82.1, 79.9,
68.9, 59.4, 57.4, 56.3, 52.7, 51.0, 29.9, 28.9, 28.5, 28.1, 27.3, 25.8, 25.6,
18.3; additional carbons identiﬁed by HMBC, (CDCl3) d 148.0, 83.90,
83.87, 40.0. HRMS-ESI: calcd for C34H53N7O8 (MþNaþ) 710.3848,
obsd 710.3855.
4.5.4. N6-(300-Azidopropyl)-50-(Na-Boc diaminobutyric acid O-tert-
butyl ester)-50-N-hydroxyethyl-50-deoxy-20,30-bis-(O-isopropylidene)
adenosine (11d). The reactionwas carried out with 10d to yield 11d
(0.278 g, 71%) as a white foam. Mp 52e54 C. 1H NMR (CDCl3) d 8.37
(s, 1H), 7.85 (s, 1H), 6.03 (d, J¼2.1 Hz, 1H), 5.95 (br s, 1H), 5.46e5.41
(m, 2H), 5.05 (dd, J¼6.6, 4.0 Hz, 1H), 4.33e4.28 (m, 1H), 4.25e4.20
(bm, 1H), 3.81e3.73 (bm, 2H), 3.59e3.52 (m, 1H), 3.48e3.41 (m,
3H), 3.01 (br s,1H), 2.89e2.82 (m,1H), 2.71e2.47 (m, 5H), 2.02e1.92
(m, 3H), 1.76e1.66 (m,1H), 1.61 (s, 3H), 1.45 (s, 18H), 1.39 (s, 3H); 13C
NMR (CDCl3) d 172.0, 155.7, 155.1, 153.3, 139.7, 120.7, 114.8, 90.6,
85.7, 84.1, 83.5, 82.1, 79.9, 59.4, 57.4, 56.3, 52.7, 51.1, 49.3, 30.0, 29.2,
28.5, 28.1, 27.3, 25.6; additional carbons identiﬁed by HMBC,
(CDCl3) d 148.2, 38.0. HRMS-ESI: calcd for C31H50N10O8 (MþNaþ)
713.3705, obsd 713.3709.
4.5.5. N6-(400-Azidobutyl)-50-(Na-Boc diaminobutyric acid O-tert-
butyl ester)-50-N-hydroxyethyl-50-deoxy-20,30-bis-(O-isopropylidene)
adenosine (11e). The reaction was carried out with 10e to yield 11e
(0.259 g, 65%) as awhite foam. Mp 50e52 C. 1H NMR (CDCl3) d 8.34
(s,1H), 7.83 (s,1H), 6.02 (bd, J¼2.0 Hz,1H), 5.91 (br s,1H), 5.44e5.41
(bm, 2H), 5.05 (dd, J¼6.5, 4.0 Hz, 1H), 4.29 (td, J¼6.8, 4.0 Hz, 1H),
4.24e4.20 (br m, 1H), 3.68 (br s, 2H), 3.55e3.51 (m, 1H), 3.43e3.40
(m, 1H), 3.34 (t, J¼6.7 Hz, 2H), 2.84 (dd, J¼13.6, 7.0 Hz, 1H),
2.69e2.48 (m, 6H), 1.99e1.93 (m, 1H), 1.80e1.67 (m, 5H), 1.60 (s,
3H), 1.44 (s, 9H), 1.43 (s, 9H), 1.37 (s, 3H); 13C NMR (CDCl3) d 172.0,
155.7,155.1,153.3,139.6,120.6,114.7, 90.5, 85.5, 84.1, 83.5, 82.1, 79.9,
59.5, 57.4, 56.3, 52.7, 51.3, 51.1, 29.9, 28.5, 28.1, 27.3, 27.2, 26.4, 25.6;
additional carbons identiﬁed byHMBC, (CDCl3) d 148.1, 39.9. HRMS-
ESI: calcd for C32H52N10O8 (MþNaþ) 727.3862, obsd 727.3867.
4.6. General procedure for iodination and global deprotection
Iodination of the alcohol requires the reagents to be added in the
proper order to prevent reduction of azides 11d and 11e by tri-
phenylphosphine. Thus, the following order of addition was fol-
lowed for incorporating the iodine for all analogs described. I2
(0.0247 g, 0.097mmol) was added to triphenylphosphine (0.0247 g,
0.094 mmol) and imidazole (0.0064 g, 0.094 mmol) in 250 mL
CH2Cl2 at 0 C. Once triphenylphosphine was completely consumed
(monitored by TLC), the amino acid functionalized N-hydroxyethyl
adenosine (0.0619 mmol) in CH2Cl2 (150 mL) was then added and
stirred for 1 h. The reactionwas diluted with ice-chilled CH2Cl2 and
H2O and the organic layer was washed with three times with H2O.
After evaporating in vacuo, 4 N HCl-dioxane (370 mL) was added tothe iodinated adenosine in CH2Cl2 (1.8 mL) and the mixture was
heated to 40 C and stirred for 2 h. Ice-chilled H2O was added and
the aqueous layer was extracted with CH2Cl2 several times prior to
lyophilization to afford a crude light yellow solid. Compound pu-
riﬁcation was carried out using HPLC (see Supplementary data for
details). NMR analysis of the resulting analogs required the addi-
tion of TFA to the deuterated solvent for product stability. Residual
signals in the 13C spectrum resulted and appeared in the range of
162.0e161.0 and 121.0e113.0 ppm. Several carbon signals were
broadened and indistinguishable from noise by 13C and required
characterization by HMBC. Additional carbon signals from the alkyl
linkers were doubled and listed as the major and minor signals
where observed.
4.6.1. N6-(Prop-200-ynyl)-50-(diaminobutyric acid)-50-N-iodoethyl-50-
deoxyadenosine ammonium hydrochloride (5a). The reaction was
carried out with 11a and the crude product was puriﬁed by HPLC
(product eluted at 8.23min; see Fig. S2 in SD) to afford 5a as awhite
solid (0.0098 g, 28%). Mp 131 C (dec). 1H NMR (1% TFA in CD3OD)
d 8.47 (s, 1H), 8.41 (br s, 1H), 6.12 (d, J¼4.2 Hz, 1H), 4.77 (t, J¼4.3 Hz,
1H), 4.50e4.42 (m, 4H), 4.10 (dd, J¼7.6, 5.6 Hz, 1H), 3.81e3.75 (m,
1H), 3.68e3.61 (m, 3H), 3.58e3.41 (m, 4H), 2.78 (t, J¼2.5 Hz, 1H),
2.45e2.37 (m, 1H), 2.31e2.25 (m, 1H); 13C NMR (1% TFA in CD3OD)
d 170.8, 143.5, 121.5, 92.1, 80.2, 79.2, 74.4, 73.9, 73.5, 57.4, 56.1, 51.8,
51.4, 31.6, 26.1, 8.0; additional carbons identiﬁed by HMBC, (1%
TFA in CD3OD) d 152.6, 149.8, 148.9. HRMS-ESI: calcd for
C19H27IN7O5 (Mþ) 560.1113, obsd 560.1114.
4.6.2. N6-(But-300-ynyl)-50-(diaminobutyric acid)-50-N-iodoethyl-50-
deoxyadenosine ammonium hydrochloride (5b). The reaction was
carried out with 11b and the crude product was puriﬁed by HPLC
(product eluted at 8.33min; see Fig. S3 in SD) to afford 5b as awhite
solid (0.010 g, 28%). Mp 136 C (dec). 1H NMR (1% TFA in CD3OD,
40 C) d 8.46 (s, 2H), 6.14 (d, J¼4.0 Hz, 1H), 4.77 (t, J¼4.5 Hz, 1H),
4.50e4.45 (m, 2H), 4.12 (dd, J¼7.5, 5.5 Hz, 1H), 3.82e3.74 (m, 2H),
3.68e3.63 (m, 3H), 3.58e3.43 (m, 5H), 2.70e2.67 (m, 2H),
2.43e2.40 (m, 1H), 2.35 (t, J¼2.6 Hz, 1H), 2.33e2.27 (m, 1H); 13C
NMR (1% TFA in CD3OD) d 170.9, 143.5, 121.3, 92.0, 81.3, 80.3, 74.4,
73.5, 71.8, 57.4, 56.1, 51.9, 51.6, 41.7, 26.1, 19.6, 7.8; carbons iden-
tiﬁed to be doubled, (1% TFA in CD3OD) d 41.7, 19.6 (major) and 44.0,
20.4 (minor); additional carbons identiﬁed by HMBC, (1% TFA in
CD3OD) d 151.4, 148.4, 147.5. HRMS-ESI: calcd for C20H29IN7O5 (Mþ)
574.1269, obsd 574.1271.
4.6.3. N6-(Hex-500-ynyl)-50-(diaminobutyric acid)-50-N-iodoethyl-50-
deoxyadenosine ammonium hydrochloride (5c). The reaction was
carried out with 11c and the crude product was puriﬁed by HPLC
(product eluted at 8.93min; see Fig. S4 in SD) to afford 5c as awhite
solid (0.013 g, 35%). Mp 142 C (dec). 1H NMR (1% TFA in CD3OD)
d 8.44 (s, 2H), 6.12 (d, J¼4.1 Hz,1H), 4.74 (t, J¼4.5 Hz,1H), 4.48e4.43
(m, 2H), 4.11 (dd, J¼7.4, 5.8 Hz, 1H), 3.76e3.60 (m, 6H), 3.53e3.42
(m, 4H), 2.49e2.38 (m, 1H), 2.32e2.23 (m, 3H), 2.19 (br s, 1H),
1.93e1.87 (m, 2H). 1.70e1.64 (m, 2H); 13C NMR (1% TFA in CD3OD)
d 170.9, 143.8, 92.1, 84.3, 80.2, 74.5, 73.5, 70.1, 57.4, 56.1, 51.8, 51.5,
26.7, 26.1, 18.7, 8.0; carbons identiﬁed to be doubled, (1% TFA in
CD3OD) d 42.8, 28.6 (major) and 45.0, 29.8 (minor); due to peak
doubling in the range of 151.0e146.0 and 121.5e120.0, the follow-
ing carbons were identiﬁed by HMBC, (1% TFA in CD3OD) d 151.5,
147.5, 146.5, 121.3. HRMS-ESI: calcd for C22H33IN7O5 (Mþ) 602.1582,
obsd 602.1584.
4.6.4. N6-(300-Azidopropyl)-50-(diaminobutyric acid)-50-N-iodoethyl-
50-deoxyadenosine ammonium hydrochloride (6a). The reactionwas
carried out with 11d and the crude product was puriﬁed by HPLC
(product eluted at 8.62 min see Fig. S5 in SD) to afford 6a as a white
solid (0.0094 g, 25%). Mp 125 C (dec). 1H NMR (1% TFA in CD3OD,
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4.47e4.42 (m, 2H), 4.09 (dd, J¼7.4, 5.5 Hz, 1H), 3.83e3.64 (m, 3H),
3.62e3.55 (m, 3H), 3.53e3.40 (m, 6H), 2.44e2.35 (m, 1H),
2.29e2.22 (m, 1H), 2.02 (p, J¼6.8 Hz, 2H); 13C NMR (1% TFA in
CD3OD) 171.0, 143.7, 121.4, 92.0, 80.3, 74.5, 73.5, 57.4, 56.1, 52.0, 51.7,
40.4, 26.2, 7.7; carbons identiﬁed to be doubled, (1% TFA in
CD3OD) d 42.6, 29.0 (major) and 43.0, 30.0 (minor); additional
carbons identiﬁed by HMBC, (1% TFA in CD3OD) d 151.5, 147.9, 147.3.
HRMS-ESI: calcd for C19H30IN10O5 (Mþ) 605.1440, obsd 605.1441.
4.6.5. N6-(400-Azidobutyl)-50-(diaminobutyric acid)-50-N-iodoethyl-
50-deoxyadenosine ammonium hydrochloride (6b). The reaction was
carried out with 11e and the crude product was puriﬁed by HPLC
(product eluted at 8.95min; see Fig. S6 in SD) to afford 6b as awhite
solid (0.0096 g, 25%). Mp 120 C (dec). 1H NMR (1% TFA in CD3OD)
d 8.44 (s, 1H), 8.41 (s, 1H), 6.11 (br s, 1H), 4.76e4.74 (m, 1H),
4.47e4.42 (m, 2H), 4.09 (dd, J¼7.5, 5.5 Hz, 1H), 3.78e3.58 (m, 6H),
3.52e3.38 (m, 6H), 2.43e2.36 (m,1H), 2.28e2.21 (m,1H), 1.87e1.81
(m, 2H), 1.76e1.70 (m, 2H); 13C NMR (1% TFA in CD3OD) d 171.0,
143.9, 92.1, 80.2, 74.5, 73.5, 57.4, 56.0, 52.0, 51.6, 44.9, 42.7, 26.9,
26.1,7.9; carbon identiﬁed to be doubled, (1% TFA in CD3OD) d 27.1
(major) and 28.0 (minor); due to peak doubling in the range of
151.5e146.0 and 121.5e120.0, the following carbons were identi-
ﬁed by HMBC, (1% TFA in CD3OD) d 151.2, 148.2, 147.1, 121.2. HRMS-
ESI: calcd for C20H32IN10O5 (Mþ) 619.1596, obsd 619.1597.
4.7. Linearization of pUC19
Plasmid DNA was linearized prior to conducting MTase-
dependent labeling. The following procedure was carried out as
described by the manufacturer: pUC19 was linearized with R.EcoRI
(2 U per mg DNA) in R.EcoRI buffer (ﬁnal DNA concentration of
0.1 mg/mL) at 37 C for 1 h and followed heat inactivation at 65 C for
20 min. The linearized pUC19 was used without subsequent
puriﬁcation.
4.8. Restriction/protection assay with M.TaqI
DNA reaction mixtures for each SAM analog were prepared as
previously described.10,15 Brieﬂy, DNA reaction mixtures were
prepared by the addition of appropriate analog stock solutions in
NEBuffer 4 (ﬁnal reaction volume was 20 mL). The ﬁnal DNA con-
centration was 0.025 mg/mL and M.TaqI was 54 U per mg DNA; the
ﬁnal concentrations of the SAM analogs ranged from 100 nM to
10 mM for the speciﬁc reaction sequence. All reactions were in-
cubated at 65 C for 4 h. The extent of DNAmodiﬁcation by the SAM
analogs was analyzed by the addition of R.TaqI (4 U per mg DNA in
10 mL NEBuffer 4), followed by incubation at 65 C for 1 h. Pro-
teinase K (0.02 U in 5 mL H2O) was added to each reaction, which
were then incubated for 1 h at 37 C. Agarose gel loading dye wasadded to each reaction and the extent of DNA modiﬁcation was
visualized by electrophoresis on a 2% agarose gel containing
ethidium bromide.Acknowledgements
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